Delcath Systems Publishes Positive Subgroup Results from Phase 3 FOCUS Study of HEPZATO in Metastatic Uveal Melanoma

Reuters2025-12-31

<a href="https://laohu8.com/S/DCTH">Delcath Systems</a> Publishes Positive Subgroup Results from Phase 3 FOCUS Study of HEPZATO in Metastatic Uveal Melanoma

Delcath Systems Inc. announced the publication of subgroup analyses from the Phase 3 FOCUS study evaluating the Melphalan/Hepatic Delivery System (HEPZATO KIT) in patients with unresectable metastatic uveal melanoma. The results, published in the Journal of Cancer Research and Clinical Oncology, assessed efficacy and safety across subgroups defined by age, sex, geographic region, liver tumor involvement, hepatic tumor burden, presence of extrahepatic lesions, baseline LDH levels, and number of prior therapies. The analyses found a consistent safety profile and efficacy across the evaluated subgroups, with no evidence of cumulative toxicity or treatment-related deaths. These results have already been published and contributed to the FDA approval of the HEPZATO KIT for this indication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251231288521) on December 31, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2595193771?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-31 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595193771","market":"fut","top_or_hot":-1,"title":"Delcath Systems Publishes Positive Subgroup Results from Phase 3 FOCUS Study of HEPZATO in Metastatic Uveal Melanoma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DCTH\">Delcath Systems</a> Publishes Positive Subgroup Results from Phase 3 FOCUS Study of HEPZATO in Metastatic Uveal Melanoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Delcath Systems Inc. announced the publication of subgroup analyses from the Phase 3 FOCUS study evaluating the Melphalan/Hepatic Delivery System (HEPZATO KIT) in patients with unresectable metastatic uveal melanoma. The results, published in the Journal of Cancer Research and Clinical Oncology, assessed efficacy and safety across subgroups defined by age, sex, geographic region, liver tumor involvement, hepatic tumor burden, presence of extrahepatic lesions, baseline LDH levels, and number of prior therapies. The analyses found a consistent safety profile and efficacy across the evaluated subgroups, with no evidence of cumulative toxicity or treatment-related deaths. These results have already been published and contributed to the FDA approval of the HEPZATO KIT for this indication.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251231288521) on December 31, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Delcath Systems Publishes Positive Subgroup Results from Phase 3 FOCUS Study of HEPZATO in Metastatic Uveal Melanoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDelcath Systems Publishes Positive Subgroup Results from Phase 3 FOCUS Study of HEPZATO in Metastatic Uveal Melanoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-31 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DCTH\">Delcath Systems</a> Publishes Positive Subgroup Results from Phase 3 FOCUS Study of HEPZATO in Metastatic Uveal Melanoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Delcath Systems Inc. announced the publication of subgroup analyses from the Phase 3 FOCUS study evaluating the Melphalan/Hepatic Delivery System (HEPZATO KIT) in patients with unresectable metastatic uveal melanoma. The results, published in the Journal of Cancer Research and Clinical Oncology, assessed efficacy and safety across subgroups defined by age, sex, geographic region, liver tumor involvement, hepatic tumor burden, presence of extrahepatic lesions, baseline LDH levels, and number of prior therapies. The analyses found a consistent safety profile and efficacy across the evaluated subgroups, with no evidence of cumulative toxicity or treatment-related deaths. These results have already been published and contributed to the FDA approval of the HEPZATO KIT for this indication.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251231288521) on December 31, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCTH","symbol_name":"迪卡斯","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDLc18x81:1","article_id":"2595193771","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595193771","pubTimestamp":1767186036,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Delcath Systems Inc. announced the publication of subgroup analyses from the Phase 3 FOCUS study evaluating the Melphalan/Hepatic Delivery System  in patients with unresectable metastatic uveal melanoma. The results, published in the Journal of Cancer Research and Clinical Oncology, assessed efficacy and safety across subgroups defined by age, sex, geographic region, liver tumor involvement, hepatic tumor burden, presence of extrahepatic lesions, baseline LDH levels, and number of prior therapies. The analyses found a consistent safety profile and efficacy across the evaluated subgroups, with no evidence of cumulative toxicity or treatment-related deaths. These results have already been published and contributed to the FDA approval of the HEPZATO KIT for this indication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational pur","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCTH":"迪卡斯","BK4082":"医疗保健设备"},"translate_title":"Delcath Systems公布HEPZATO治疗转移性葡萄膜黑色素瘤3期FOCUS研究的阳性亚组结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCTH":0.9},"content_text":"Delcath Systems Publishes Positive Subgroup Results from Phase 3 FOCUS Study of HEPZATO in Metastatic Uveal Melanoma\n    \n\n        Delcath Systems Inc. announced the publication of subgroup analyses from the Phase 3 FOCUS study evaluating the Melphalan/Hepatic Delivery System (HEPZATO KIT) in patients with unresectable metastatic uveal melanoma. The results, published in the Journal of Cancer Research and Clinical Oncology, assessed efficacy and safety across subgroups defined by age, sex, geographic region, liver tumor involvement, hepatic tumor burden, presence of extrahepatic lesions, baseline LDH levels, and number of prior therapies. The analyses found a consistent safety profile and efficacy across the evaluated subgroups, with no evidence of cumulative toxicity or treatment-related deaths. These results have already been published and contributed to the FDA approval of the HEPZATO KIT for this indication.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251231288521) on December 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595193771","isCrawlerRequest":true}